Clinical Trial Update: STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating toxicity-adjusted dosing in small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN